9:36 AM
 | 
Mar 08, 2019
 |  BC Week In Review  |  Company News  |  Regulatory

Esperion submits NDAs to FDA for LDL-C lowering products, EMA starts review

Esperion said it submitted two NDAs to FDA for bempedoic acid (ETC-1002) and a bempedoic acid/ezetimibe combination tablet to treat...

Read the full 79 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review